Fuji Pharma Co., Ltd. (TYO:4554)
1,845.00
+7.00 (0.38%)
Aug 25, 2026, 3:30 PM JST
Fuji Pharma Revenue
Fuji Pharma had revenue of 15.67B JPY in the quarter ending June 30, 2026, with 21.83% growth. This brings the company's revenue in the last twelve months to 60.11B, up 20.36% year-over-year. In the fiscal year ending September 30, 2025, Fuji Pharma had annual revenue of 51.68B with 12.01% growth.
Revenue (ttm)
60.11B
Revenue Growth
+20.36%
P/S Ratio
0.80
Revenue / Employee
34.15M
Employees
1,760
Market Cap
48.19B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 51.68B | 5.54B | 12.01% |
| Sep 30, 2024 | 46.14B | 5.25B | 12.84% |
| Sep 30, 2023 | 40.89B | 5.46B | 15.42% |
| Sep 30, 2022 | 35.43B | 1.44B | 4.22% |
| Sep 30, 2021 | 33.99B | 197.00M | 0.58% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KYORIN Pharmaceutical | 125.68B |
| Mochida Pharmaceutical | 122.04B |
| Kissei Pharmaceutical | 98.60B |
| Zeria Pharmaceutical | 91.12B |
| Kaken Pharmaceutical | 88.16B |
| ASKA Pharmaceutical Holdings | 70.87B |
| Pharma Foods International | 67.00B |
| Fuso Pharmaceutical Industries,Ltd. | 62.85B |
Fuji Pharma News
- 1 year ago - Alvotech Receives Marketing Approval In Japan For Three New Biosimilars - Nasdaq
- 1 year ago - Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility - Benzinga
- 1 year ago - Olic anticipates buoyant demand for contraceptives - Bangkok Post